Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neflamapimod placebo-controlled Phase 2 study in dementia with Lewy bodies
NL-OMON49197Phase 2Active, not recruiting
- Sponsor
- CervoMed
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dementia with Lewy bodies (DLB) comparing Neflamapimod with Placebo (2 arms). Primary endpoint: Change in composite neuropsychological test battery score. Started Sep 2019; status: active, not recruiting.
02
Drugs
neflamapimod
03
Conditions
dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NL-OMON49197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49197.